ACIU

AC Immune SA (ACIU) - Form 20-F Summary

Business Context and Reporting Period

Company: AC Immune SA
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: AC Immune is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases (Alzheimer's, Parkinson's, and others) using two proprietary platforms: SupraAntigen (active immunotherapies) and Morphomer (small molecules and diagnostics). The company has no approved products and generates revenue primarily through collaboration agreements and grants.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by CHF 23.7 million (87%) to CHF 3.6 million. The 2024 period included a CHF 24.6 million milestone payment from Janssen Pharmaceuticals for the ReTain trial, which did not recur in 2025. 2025 revenue was primarily derived from development services under the Takeda agreement.
• Increased Net Loss: Net loss widened by CHF 19.5 million to CHF 70.4 million, driven by the absence of the large Janssen milestone and continued R&D investments.
• Liquidity Reduction: Total liquidity decreased by CHF 74.1 million to CHF 91.4 million, primarily due to R&D spending and a net maturation of short-term financial assets (CHF 64.6 million) in 2025 compared to net investments in 2024.
• Restructuring: The company recorded CHF 0.5 million in net restructuring expenses in 2025 (nil in 2024) following a strategic review in September 2025 to reduce costs and sharpen focus on key assets.
• Exchange Rate Impact: A CHF 2.8 million loss in exchange differences was recorded in 2025 due to the depreciation of foreign currencies (primarily USD) against the Swiss Franc.

Guidance, Outlook, and Risks

Outlook & Capital Resources: Management believes existing capital resources (CHF 91.4 million) are sufficient to meet projected operating requirements until the end of Q3 2027, assuming no additional milestone payments. The company expects to continue incurring significant operating losses as it advances clinical programs.

Key Clinical Updates:

• ACI-7104.056 (Parkinson's): Phase 2 VacSYn trial interim results showed strong antibody responses and stabilization of disease biomarkers, supporting progression to advanced development.
• ACI-24.060 (Alzheimer's): Phase 1b/2 ABATE trial continues; no ARIA-E reported. Subject of an exclusive option and license agreement with Takeda (upfront payment of USD 100 million received in 2024).
• ACI-35.030 (Alzheimer's): Phase 2b ReTain trial enrollment was temporarily paused by Janssen to evaluate recruitment aspects; no safety concerns cited.
• ACI-19764 (NLRP3 Inhibitor): First-in-human Phase 1 study initiated in early 2026.

Material Risks:

• Regulatory & Clinical Failure: High risk of failure in clinical trials; no products approved for sale.
• Liquidity: Dependence on future capital raises or milestone payments to fund operations beyond late 2027.
• Collaboration Dependence: Reliance on partners (Janssen, Takeda, Lilly, Lantheus) for development and commercialization; risk of termination or failure to exercise options.
• Intellectual Property: Risks related to patent expiration, infringement claims, and the Unified Patent Court (UPC) in Europe.
• Geopolitical & Trade: Exposure to U.S. tariffs on Swiss imports (reduced to 15% in late 2025) and potential supply chain disruptions.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the Q3 2027 liquidity projection given the high burn rate and potential for accelerated clinical spending.
• Takeda Option Exercise: Monitor the status of the Takeda option exercise for ACI-24.060, which is critical for future revenue recognition and development funding.
• Janssen ReTain Trial: Confirm the resolution of the enrollment pause in the ACI-35.030 ReTain trial and its impact on future milestone payments.
• IPR&D Asset Valuation: Review the valuation assumptions for the CHF 50.4 million in-process research and development (IPR&D) asset, which is subject to annual impairment testing.
• PFIC Status: Confirm the company's Passive Foreign Investment Company (PFIC) status for U.S. investors, as the filing notes uncertainty regarding future years despite a likely non-PFIC status for 2025.